Peptide Therapeutics Industry Overview
The global peptide therapeutics market size is expected to reach USD 68.7 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2022 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.
Peptide Therapeutics Market Segmentation
Grand View Research has segmented the global peptide therapeutics market by application, type, type of manufacturers, route of administration, synthesis technology, and region:
Based on the Application Insights, the market is segmented into Cancer, Metabolic, Cardiovascular Disorder, Respiratory, GIT, Antiinfection, Pain, Dermatology, CNS, Renal, Others.
- The metabolic segment dominated the market with a revenue share of over 35.0% in 2021.
- The prevalence of metabolic disorders is rapidly increasing. Sedentism, unhealthy eating habits, and excessive alcohol consumption have all contributed to an increase in the incidence of these disorders.
- Cancer emerged as the second-largest segment in 2021. The significant components responsible for this segment growth are rising cancer prevalence worldwide and increased prescription of peptide therapeutics for cancer treatment. Increased demand for efficient and fast-acting therapeutics is expected to fuel growth during the forecast period.
Based on the Type Insights, the market is segmented into Generic, Innovative.
- The innovative segment dominated the market in 2021 with a revenue share of over 60.0% owing to the increased R&D investments by large pharmaceutical companies in the discovery and development of new drugs and high prescription rates. The market is divided into generic and innovative segments based on type.
- The generic segment is expected to grow at a rapid pace during the forecast period. Rising healthcare spending and increased federal government healthcare spending are expected to drive generic drug adoption. The loss of patents on many branded drugs is also believed to be a key factor driving the generic segment.
Based on the Type of Manufacturers Insights, the market is segmented into In-house, Outsourced.
- The in-house manufacturing segment held the largest revenue share of over 65.0% in 2021. Most of the key players are involved in developing peptide therapeutics in-house owing to stringent regulations and the high cost of outsourcing. As large pharmaceutical companies have proper infrastructure for large-scale production and advanced technology, these companies prefer in-house manufacturing.
- The outsourcing activities for manufacturing are also estimated to grow during the forecast period due to difficulties in manufacturing therapeutics with high-quality standards. The companies prefer to outsource the Active Pharmaceutical Ingredient (API) from companies having high-end technology and expertise for manufacturing various types of peptides.
- Peptide manufacturing is a complex procedure and it requires advanced technologies such as Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), or Hybrid for purification and synthesis of high-quality products, which results in the high cost of manufacturing.
Based on the Route of Administration Insights, the market is segmented into Parenteral Route, Oral Route, Pulmonary, Mucosal, Others.
- The parenteral route of administration dominated the market in 2021 with a revenue share of over 80.0%. This is attributed mainly to the high adoption rate, faster delivery of drugs, and ease of application. The biopharmaceuticals giants are continuously exploring new methods of drug delivery pertinent to peptides.
- Novel drug delivery technologies are now being assessed for efficacy with engineered molecules having advanced PEGylation in an attempt to improve drug delivery performance and patient compliance through better modes of drug delivery. Patient compliance and acceptability are major advantages of the oral route of drug administration.
- The pulmonary route is acknowledged for peptide and protein administration owing to the physiological characteristics of the respiratory system. Several proteins and peptides are currently undergoing clinical trials and awaiting approval via pulmonary usage.
Based on the Synthesis Technology Insights, the market is segmented into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology.
- The LPPS segment dominated the market with a share of over 45.0% in 2021 owing to the rising demand for pure peptides for the development of efficient therapeutics. However, issues such as higher consumption of time are responsible for shifting consumers’ preferences to faster and more effective methods such as SPPS.
- SPPS lowers the synthesis time and is used in a wide range of production procedures. Moreover, higher efficiency during the synthesis of longer peptides is another driver for the market. Furthermore, associated automation, scalability, and enhanced control over the physicochemical properties of peptides are expected to drive the market over the forecast period.
- Hybrid technology is expected to witness lucrative growth in the years to come owing to associated benefits such as compatibility with both liquid-phase synthesis and solid-phase synthesis.
Peptide Therapeutics Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies Profile & Market Share Insights
The development of new products and technological advancements are key strategies undertaken by the companies to gain market position. Moreover, increasing collaborations for undertaking trials of new drugs are estimated to increase competitive rivalry.
Some prominent players in the global peptide therapeutics market include
- Eli Lilly and Company
- Pfizer, Inc.
- Amgen, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Lonza Inc.
- Sanofi
- Bristol-Myers Squibb (BMS)
- AstraZeneca PLC
- GlaxoSmithKline plc (GSK)
- Novartis AG
- Novo Nordisk A/S
Order a free sample PDF of the Peptide Therapeutics Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
